Merck recently gained approval for a vaccine called Zostavax for preventing herpes zoster reactivation in elderly people. This live virus vaccine is unusual in that it is to prevent reemergence, not to prevent initial infection. Can the same concept be used for recurrent herpes simplex infection which is much more disabling than herpes zoster in younger people?
Dermatologist | Innovator | GenAI Connoisseur | Educator | Software Engineer, coding the future of intelligent medicine! | Consult free if you serve the underprivileged! | Pull requests are always welcome!
Latest posts by Bell Eapen (see all)
- Pragmatic Research That Builds and Travels - December 9, 2025
- Are we trapped in a matrix? - November 18, 2025
- Design Science Research in Healthcare: Bridging the Gap Between Ideas and Impact - November 11, 2025